Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy
- PMID: 29402461
- DOI: 10.1016/j.imbio.2018.01.001
Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy
Abstract
Diabetic retinopathy (DR) is a multifactorial microvascular disease induced by hyperglycemia and subsequent metabolic abnormalities. The resulting cell stress causes a sequela of events that ultimately can lead to severe vision impairment and blindness. The early stages are characterized by activation of glia and loss of pericytes, endothelial cells (EC) and neuronal cells. The integrity of the retinal microvasculature becomes affected, and, as a possible late response, macular edema may develop as a common reason for vision loss in patients with non-proliferative DR. Moreover, the local ischemia can trigger vasoproliferation leading to vision-threating proliferative DR (PDR) in humans. Available treatment options include control of metabolic and hemodynamic factors. Timely intervention of advanced DR stages with laser photocoagulation, intraocular anti-vascular endothelial growth factor (VEGF) or glucocorticoid drugs can reduce vision loss. As the pathology involves cell loss of both the vascular and neuroglial compartments, cell replacement strategies by stem and progenitor cells have gained considerable interest in the past years. Compared to other disease entities, so far little is known about the efficacy and potential mode of action of cell therapy in treatment of DR. In preclinical models of DR different cell types have been applied ranging from embryonic or induced pluripotent stem cells, hematopoietic stem cells, and endothelial progenitor cells to mesenchymal stromal cells (MSC). The latter cell population can combine various modes of action (MoA), thus they are among the most intensely tested cell types in cell therapy. The aim of this review is to discuss the rationale for using MSC as potential cell therapy to treat DR. Accordingly, we will revise identified MoA of MSCs and speculate how these may support the repair of the damaged retina.
Keywords: Adipose stromal cells; Diabetic retinopathy; Immunomodulation; Mesenchymal stem cells; Mode of action; Paracrine function; Pericytes.
Copyright © 2018 Elsevier GmbH. All rights reserved.
Similar articles
-
Adipose-derived mesenchymal stromal cells reverse high glucose-induced reduction of angiogenesis in human retinal microvascular endothelial cells.Cytotherapy. 2020 May;22(5):261-275. doi: 10.1016/j.jcyt.2020.02.005. Epub 2020 Apr 1. Cytotherapy. 2020. PMID: 32247542
-
Could donor multipotent mesenchymal stromal cells prevent or delay the onset of diabetic retinopathy?Acta Ophthalmol. 2014 Mar;92(2):e86-95. doi: 10.1111/aos.12113. Epub 2013 Jun 15. Acta Ophthalmol. 2014. PMID: 23773776 Review.
-
Research on the role of exosomes secreted by immortalized adipose-derived mesenchymal stem cells differentiated into pericytes in the repair of high glucose-induced retinal vascular endothelial cell damage.Exp Eye Res. 2024 Oct;247:110046. doi: 10.1016/j.exer.2024.110046. Epub 2024 Aug 14. Exp Eye Res. 2024. PMID: 39147191
-
Clinical-grade human embryonic stem cell-derived mesenchymal stromal cells ameliorate diabetic retinopathy in db/db mice.Cytotherapy. 2024 Jun;26(6):606-615. doi: 10.1016/j.jcyt.2024.02.020. Epub 2024 Mar 4. Cytotherapy. 2024. PMID: 38483364
-
Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion.Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFj1-ORSFj10. doi: 10.1167/iovs.15-17594. Invest Ophthalmol Vis Sci. 2016. PMID: 27116667 Review.
Cited by
-
Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials.Cells. 2021 Mar 7;10(3):588. doi: 10.3390/cells10030588. Cells. 2021. PMID: 33799995 Free PMC article. Review.
-
Human adipose tissue-derived stromal cells act as functional pericytes in mice and suppress high-glucose-induced proinflammatory activation of bovine retinal endothelial cells.Diabetologia. 2018 Nov;61(11):2371-2385. doi: 10.1007/s00125-018-4713-0. Epub 2018 Aug 27. Diabetologia. 2018. PMID: 30151615 Free PMC article.
-
Protective effect of LIF-huMSCs on the retina of diabetic model rats.Int J Ophthalmol. 2021 Oct 18;14(10):1508-1517. doi: 10.18240/ijo.2021.10.06. eCollection 2021. Int J Ophthalmol. 2021. PMID: 34667726 Free PMC article.
-
Recent advances in understanding mesenchymal stromal cells.F1000Res. 2020 Feb 27;9:F1000 Faculty Rev-156. doi: 10.12688/f1000research.21862.1. eCollection 2020. F1000Res. 2020. PMID: 32148780 Free PMC article. Review.
-
Mesenchymal stem cells and mesenchymal stem cell-derived exosomes: a promising strategy for treating retinal degenerative diseases.Mol Med. 2025 Feb 21;31(1):75. doi: 10.1186/s10020-025-01120-w. Mol Med. 2025. PMID: 39984849 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous